In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Xigris: Taking Intensive Care in Europe

Executive Summary

Eli Lilly hopes that renewed focus on patient selection and a practical message targeted at a variety of hospital personnel--not just prescribers--can boost disappointing sales of its severe sepsis treatment, Xigris, as it gears up to launch the expensive treatment in the price-conscious and heterogeneous European market.
Advertisement

Related Content

Lonza Biologics: Responding to Changing Needs
Lilly Enlists Boehringer for Duloxetine
In Sepsis, Having the Right Drug Still May Not Be Enough
Protein C: Saving Lives, Saving Lilly

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel